Clinical Personalized Medicine for Parkinson's Disease and Implications on Sleep Dysfunction

Personalized medicine (PM) for Parkinson's disease (PD) can range from precision genomic therapies such as ambroxol in glucocerebrosidase mutation-linked PD to treatment tailored for sleep dysfunction in nonmotor subtypes of PD. Additionally, in future pharmacogenetics may also play a part by i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sleep medicine clinics Jg. 20; H. 3; S. 417
Hauptverfasser: Metta, Vinod, Popławska-Domaszewicz, Karolina, Chen, Rosabel, Chaudhuri, K Ray
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.09.2025
Schlagworte:
Humans
Parkinson Disease - complications
Parkinson Disease - drug therapy
Parkinson Disease - genetics
Parkinson Disease - therapy
Precision Medicine - methods
Sleep Wake Disorders - drug therapy
Sleep Wake Disorders - etiology
Sleep Wake Disorders - therapy
Pharmacogenetics
Sleep dysfunction
Precision medicine
Genomic medicine
Insomnia pharmacogenetics
Personalised medicine
Subtype
Parkinson’s disease
ISSN:1556-4088
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Personalized medicine (PM) for Parkinson's disease (PD) can range from precision genomic therapies such as ambroxol in glucocerebrosidase mutation-linked PD to treatment tailored for sleep dysfunction in nonmotor subtypes of PD. Additionally, in future pharmacogenetics may also play a part by identification of PD patients susceptible to specific sleep problems such as sudden onset of sleep and facilitate avoiding drugs that may cause these side effects. Age, physical exercise, comorbidities can also drive quality of sleep in PD and form important part of the Parkinson's dashboard-led strand of PM.
ISSN:1556-4088
DOI:10.1016/j.jsmc.2025.06.006